GEROTHERAPEUTIX is actively growing a database of newly generated MitoXcel geropeptide candidates, which are then tested in a proprietary set of in vitro assays to assess their potencies for Mechanism 1 and 2. Through an iterative learning process, MitoXcelAI™—the platform’s proprietary artificial intelligence engine—analyzes this growing dataset to train and refine predictive algorithms. This continuous feedback loop enhances the design rules that define MitoXcel™ Technology, much like the iPhone periodically updates its operating system, ensuring its evolution as a best-in-class, information-engineered solution for generating novel geropeptides that combat age-related decline.
